Kronos Bio Announces Changes to Board of Directors
Katherine Vega Stultz appointed to Board
Current Board member Otello Stampacchia, Ph.D., stepped down
SAN MATEO, Calif. and CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq:KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Katherine Vega Stultz to its Board of Directors, replacing Otello Stampacchia, Ph.D., who stepped down as of March 31, 2023.
Related news for (KRON)
- MoBot alert highlights: NASDAQ: ZENA, NASDAQ: ZJK, NASDAQ: KRON, NASDAQ: SILO, NASDAQ: TGL (06/05/25 08:00 AM)
- Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right
- Kronos Bio Announces CEO Transition and Reduction in Force
- Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives
- Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives